MARCO and neoplasm: Studies have demonstrated that targeting MARCO with specific antibodies can suppress TAM activation, shift macrophages toward the M1 phenotype, and enhance the effectiveness of anti-tumor immunotherapies in breast, colon cancer, and melanoma models (172, 173).